Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy

Kévin Le Duc1,2*, Sixtine Gilliot3,4, Jean Benoit Baudelet5, Sébastien Mur1, Mohamed Riadh Boukhris1, Olivia Domanski5, Pascal Odou3,4 and Laurent Storme1,2

1Department of Neonatology, Jeanne de Flandre Hospital, University Hospital of Lille, Lille, France, 2ULR2694 Metrics–Perinatal Environment and Health, University of Lille, Lille, France, 3ULR 7365–GRITA–Groupe de Recherche sur Les Formes Injectables et Les Technologies Associées, Université de Lille, CHU Lille, Lille, France, 4Institut de Pharmacie, CHU Lille, Lille, France, 5Department of Pediatric Cardiology, Institut Coeur Poumon, University Hospital of Lille, Lille, France

Background: The use of non-steroidal anti-inflammatory drugs (NSAIDs) during the third trimester of pregnancy can cause premature constriction of the ductus arteriosus. This report describes a case of in utero narrowing of the ductus arteriosus (DA) diagnosed postnatally in a baby with Persistent Pulmonary Hypertension of the Newborn (PPHN), after maternal use of Diclofenac-Epolamine 140 mg patch during the second and third trimester.

Case Presentation: A fetal ultrasound revealed an enlarged hypertrophic right ventricle at 32 weeks of gestation. Detailed questioning of the mother highlighted that topical Diclofenac (FLECTOR®) had been used at 26 and at 31 weeks of gestation. An echocardiography performed 8 h postnatally showed supra-systemic pulmonary hypertension, a restrictive ductus arteriosus and a dilated right ventricle. The newborn was treated by inhaled nitric oxide and oral Sildenafil and was discharged from hospital on day 24. He had a complete normalization of his pulmonary vascular resistance on day 48.

Conclusion: This case illustrates the potential fetal and neonatal complications associated with maternal topical Diclofenac medication during pregnancy resulting in antenatal closure of the DA.

Keywords: PPHN (persistent pulmonary hypertension of the newborn), NSAID (non-steroidal anti-inflammatory drug), ductus arteriosus, NICU (neonatal intensive care unit), pregnancy, neonate

INTRODUCTION

During pregnancy, the right ventricular output is mostly directed from the pulmonary artery to the aorta, which contributes to systemic circulation (Rasanen et al., 1996). Patency of the ductus arteriosus is maintained during gestation by an elevated concentration of prostaglandin (PGE2) and a low fetal blood partial pressure of O2 (Clyman, 2006).

The use of non-steroidal anti-inflammatory drugs (NSAIDs) during the third trimester of pregnancy can cause premature constriction of the ductus arteriosus by inhibiting cyclooxygenase 2 (COX-2) (Van Marter et al., 1996; Gewillig et al., 2009; Storme et al., 2013).
Diclofenac, a NSAID, was found to show the greatest potency for inhibition of phorbol ester-induced PGE2 production (reflecting inflammation induced COX-2 activity) compared with a similar range of NSAIDs in human fibroblasts in vitro. It has also been classified as one of the most potent inducers of ductus arteriosus constriction in rats (Momma et al., 1984; Cordero et al., 2001). Diclofenac is a low molecular weight molecule of 318.15 Da which crosses trophoblastic membranes easily, with a mean maternal/fetal drug ratio that is inferior to one, indicating the drug may accumulate in fetal tissue over time (Siu et al., 2000). The placental transport of NSAIDs involves specific transports including monocarboxylate transporter 4 - a proton dependent transporter, which transports L-lactic acid as a substrate (Emoto et al., 2002). This case report highlights the importance of informing pregnant women about the risk of self-medication and topical NSAID use during pregnancy.

**CASE DESCRIPTION**

We report the case of a newborn infant with persistent pulmonary hypertension of the newborn (PPHN) resulting from antenatal narrowing of the ductus arteriosus related to maternal application of topical Diclofenac during the second trimester of pregnancy. The infant was born to a 35-year-old mother both the course of the pregnancy—the mother's second—and antenatal blood tests were unremarkable. As recommended by the French National Technical Committee on Prenatal Ultrasound Screening, three antenatal echography were performed during the first, second were described as normal. The third revealed cardiac ventricular asymmetry and a right ventricle cardiac hypertrophy (Figure 1).

A male infant weighing 3,470 g (50th-90th percentile) was delivered at 39 weeks of gestation by a planned cesarean section for breech presentation. Apgar scores were 10 at both 1 and 5 min. A pediatrician examined the baby 8 h after birth for moderate dyspnea. Cardiac auscultation revealed a systolic ejection murmur loudest over the pulmonary valve Pre-ductal oxygen saturation was 88% in room air, which increased to 98% with high flow nasal cannula at 2 L/Kg/min and O2 supplementation (from 30 to 100% FiO2). The newborn was admitted to the Neonatal Intensive Care Unit where an echocardiography showed supra-systemic pulmonary hypertension with tricuspid regurgitation blood flow velocities of 60 mmHg (Figure 2), whereas systolic blood pressure was 54 mmHg. An accelerated right-to-left shunting was recorded across a restrictive DA. No cardiac malformation was found. Our hypotheses were therefore:

- a premature closure of the ductus arteriosus during pregnancy,
- a premature closure of the foramen ovale,
- or an alveolar capillary dysplasia.

A CT scan with contrast was performed 5 days after birth, showing an aneurysm of the inter-atrial septum without shunting, a dilated right ventricle and a markedly dilated main pulmonary artery.

The newborn was managed by inhaled NO (20 ppm), alprostadil infusion (0.02 µg·kg·min⁻¹) and high-flow oxygen supplementation through nasal canulas for 18 days. Oral Sildenafil was started on day 3 due to the persistence of pulmonary hypertension. Symptoms improved on day 17, the ductus arteriosus was closed at day 20 and the infant was discharged from hospital on day 24 with normalization of pulmonary pressures (Figure 3). Sildenafil was stopped on day 157. At the age of 1 year, the infant presented no symptoms, a normal neuro-developmental outcome and a normal echocardiography.

Rigorous and repeated anamnestic determined that the mother applied Flector® (Diclofenac-Epolamine 140 mg patch, GENEVRIER SA Laboratory) on her lumbar area for back pain at 26 and 31 weeks of gestational age. In order to further reduce the pain, a hot water bottle was also applied to the area at the same time as the patch.

**DISCUSSION**

This case reveals the risk of a sustained narrowing of the ductus arteriosus resulting in prolonged persistent pulmonary hypertension in the postnatal period after maternal use of topical diclofenac during the second trimester. Besides NSAIDs, other causes of fetal ductal constriction and PPHN have previously been reported. Acetaminophen may increase the risk of prenatal ductus arteriosus constriction, through inhibition of prostaglandin G2 synthesis. Growing body of evidence suggests a role of maternal consumption of polyphenols-rich food (green tea, orange juice, coco bean, spring vegetables), which interfere with prostaglandin metabolism, in

![Figure 1](image-url)
prenatal ductus arteriosus narrowing (Zielinsky and Busato, 2013). After rigorous questioning of the mother, no paracetamol treatment or excessive polyphenol-rich food intake were recorded.

Antenatal narrowing of the DA results in increased pulmonary artery pressure, which in turn mediates a remodeling of the vascular wall through sustained elevation of vascular stretch stress, leading to structural pulmonary hypertension (Storme et al., 2002; Larrue et al., 2005; Shima et al., 2011).

Previous studies clearly showed that DA sensitivity to constricting factors increases during the last trimester of pregnancy (Van den Veyver and Moise, 1993). The risk of indomethacin-induced fetal ductal constriction increases with advancing gestational age (Luchese et al., 2003). Second trimester fetal adverse events have been reported after prolonged NSAID exposure of at least 7 days while our case reports the occurrence of DA narrowing after two topical applications of a daily NSAID patch (48 h of total application) (Dathe et al., 2019).

Only one previous case of antenatal DA closure has been reported after maternal topical use of diclofenac during the third trimester of pregnancy. In that case, diclofenac has been applied at 35 weeks gestational age and the constriction of the ductus arteriosus was rapidly reversible at birth (Torloni et al., 2006). In this latter case report, the formulation of diclofenac incremented in DA narrowing was a gel formulation of diclofenac.
diethylamine (Cataflam Rmugel 11.6 mg/g, Novartis). It is of current knowledge that topical NSAIDs, including diclofenac diethylamine, are associated with systemic effects (Evans et al., 1995). The patch delivery in diclofenac-epolamine (DI-EP) was developed more recently to prevent the acute release of NSAIDs to the bloodstream and control the amount of active substance delivered through the skin, in contrast to that from application of bioequivalent gels or ointments of diclofenac (Goh and Lane, 2014). The pharmacokinetics parameters of diclofenac patches are expected to lengthen the time of product release in the central compartment, to reach a maximal plasmatic concentration of about 20 ng/ml (Rainsford et al., 2008). Previous studies on transplacental pharmacokinetics of diclofenac reported that the fetal peak plasma concentration was estimated to be one-tenth of the maternal value (Shintaku et al., 2012). Concerning pharmacodynamics, an animal predictive model performed on rats revealed that the concentration–response (response being DA narrowing) relationship in rat fetus was characterized by an EC50 of 1.4 ng/ml, reinforcing the plausibility of the link between diclofenac patch application and DA narrowing in our case report (Shintaku et al., 2012). Furthermore, it is likely that the use of hot water bottle for back pain may have promoted skin absorbance of the drug (Park et al., 2008; Panda et al., 2019).

There are no reports on the occurrence of systemic side effects related to a single topical NSAIDs application, when applied in conformity with recommendations of us, in current literature. The risk of occurrence is often related to misuse; in our case, the application of heat to the same area as the patch led to an increase of the drug’s absorption and the modification of the delivery profile of diclofenac. Regardings these elements, the implication of the DI-EP patch (Flector®) in the occurrence of pulmonary hypertenasion in newborn infants cannot be excluded. Furthermore, it is likely that the use of a hot water bottle for back pain may have promoted skin absorbance of the drug (Park et al., 2008; Panda et al., 2019). In light of this evidence, the role of the DI-EP patch (Flector®) on pulmonary hypertension in newborns in must be highly considered.

Cases of antenatal closure of the DA after oral use of diclofenac during the third trimester of pregnancy have more commonly been reported (Auer et al., 2004). According to the summary of product characteristics, the use of FLECTOR® patch must be avoided during the five first months of pregnancy and is strictly contraindicated during the 3rd trimester of pregnancy. Many other patches containing diclofenac as the main active substance are available on the market (Voltarenplast®, Antacalm®, Flectoreffigel®). They differ in the salt of diclofenac they contain and must be responsible for an equivalent risk of DA narrowing. Patches containing diclofenac salts are over-the-counter medications in many countries and their use does not require any medical prescription, enhancing the risk of misuse in pregnant women.

Our findings suggest that maternal educational programs should include information pertaining to topical treatments in order to prevent potentially harmful self-medication in pregnant women.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

KL, SG, SM, OB, OD, JB, PO, and LS were involved in drafting the manuscript. All authors read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

The authors thank Kelly Saint Denny for English editing.

REFERENCES

Auer, M., Brezincka, C., Eller, P., Luze, K., Schweigmann, U., and Schwarzer, P. (2004). Prenatal Diagnosis of Intrauterine Premature Closure of the Ductus Arteriosus Following Maternal Diclofenac Application. Ultrasound Obstet. Gynecol. 23, 513–516. doi:10.1002/uog.1038

Clyman, R. I. (2006). Mechanisms Regulating the Ductus Arteriosus. Neonatology 89, 330–335. doi:10.1159/000092670

Cordero, J. A., Camacho, M., Obsch, R., Domenech, J., and Vila, L. (2001). In Vitro based index of Topical Anti-inflammatory Activity to Compare a Series of NSAIDs. Eur. J. Pharm. Biopharm. 51, 135–142. doi:10.1016/S0939-6411(00)00149-1

Dathe, K., Hultzsche, S., Pritchard, L. W., and Schaefer, C. (2019). Risk Estimation of Fetal Adverse Effects after Short-Term Second Trimester Exposure to Non-steroidal Anti-inflammatory Drugs: a Literature Review. Eur. J. Clin. Pharmacol. 75, 1537–1553. doi:10.1007/s00228-019-02712-2

Emoto, A., Ushigome, F., Koyabu, N., Kajiya, H., Okabe, K., Satoh, S., et al. (2002). H(+)-linked Transport of Salicylic Acid, an NSAID, in the Human Trophoblast Cell Line BeWo. Am. J. Physiol. Cel Physiol 282, C1064–C1075. doi:10.1152/ajpcell.00179.2001

Evans, J. M., McMahon, A. D., McGilchrist, M. M., White, G., Murray, F. E., McDevitt, D. G., et al. (1995). Topical Non-steroidal Anti-inflammatory Drugs and Admission to Hospital for Upper Gastrointestinal Bleeding and Perforation: a Record Linkage Case-Control Study. BMJ 311, 22–26. doi:10.1136/bmj.311.6996.22

Gewillig, M., Brown, S. C., De Catte, L., Debeer, A., Eyskens, B., Cossey, V., et al. (2009). Premature Foetal Closure of the Arterial Duct: Clinical Presentations and Outcome. Eur. Heart J. 30, 1530–1536. doi:10.1093/eurheartj/ehp128

Goh, C. F., and Lane, M. E. (2014). Formulation of Diclofenac for Dermal Delivery. Int. J. Pharm. 473, 607–616. doi:10.1016/j.ijpharm.2014.07.052

Larrue, B., Jaillard, S., Lorthioir, M., Roubliaux, X., Butrous, G., Rakza, T., et al. (2005). Pulmonary Vascular Effects of Sildenafil on the Development of Chronic Pulmonary Hypertension in the Ovine Fetus. Am. J. Physiol. Lung Cel Mol Physiol 288, L1193–L1200. doi:10.1152/ajplung.00405.2004
Storme, L., Parker, T. A., Kinsella, J. P., Rairigh, R. L., and Abman, S. H. (2002). Chronic Hypertension Impairs Flow-Induced Vasodilation and Augments the Myogenic Response in Fetal Lung. *Am. J. Physiol. Lung Cel Mol Physiol* 282, L56–L66. doi:10.1152/ajplung.2002.282.1.L56

Torloni, M. R., Cordioli, E., Zamith, M. M., Hisaba, W. J., Nardoza, L. M., Santana, R. M., et al. (2006). Reversible Constriction of the Fetal Ductus Arteriosus after Maternal Use of Topical Diclofenac and Methyl Salicylate. *Ultrasound Obstet. Gynecol.* 27, 227–229. doi:10.1002/uog.2647

Van den Veyver, I. B., and Moise, K. J. (1993). Prostaglandin Synthetase Inhibitors in Pregnancy. *Obstet. Gynecol. Surv.* 48, 493–502. doi:10.1097/00006254-199307000-00026

Van Minter, L. J., Leviton, A., Allred, E. N., Pagano, M., Sullivan, K. F., Cohen, A., et al. (1996). Persistent Pulmonary Hypertension of the Newborn and Smoking and Aspirin and Nonsteroidal Antiinflammatory Drug Consumption during Pregnancy. *Pediatrics* 97, 658–663. doi:10.1542/peds.97.4.658

Zielinsky, P., and Busato, S. (2013). Prenatal Effects of Maternal Consumption of Polyphenol-Rich Foods in Late Pregnancy upon Fetal Ductus Arteriosus. *Birth Defects Res. C. Embryo Today* 99, 256–274. doi:10.1002/bdrc.21051

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Le Duc, Gilliot, Baudelet, Mur, Boukhris, Domanski, Odou and Storme. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.